



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Applicant: Carl M. Mendel, *et al.*

Serial No.: 10/828,607

Filed: April 24, 2004

For: TREATMENT OF NEUROPATHIC
PAIN

Examiner: L. Royds

Group Art Unit: 1614

Case No.: BBC128USC1

**CERTIFICATE OF MAILING (37 CFR
1.8 (a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450, on:

Date of Deposit: January 30, 2007

Kathleen Boettcher
Kathleen Boettcher

TRANSMITTAL LETTER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is an Information Disclosure Statement for Carl M. Mendel, *et al.*, for: TREATMENT OF NEUROPATHIC PAIN, the specification of which was filed on April 21, 2004, and received Serial No. 10/828,607.

Also enclosed are: Form PTO 1449 (in duplicate)
Return-receipt postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

Respectfully submitted,
Carl M. Mendel, *et al.*

Andrew M. Parial
Andrew M. Parial
Registration No. 50,382
Attorney for Applicants

ABBOTT LABORATORIES
Customer Number: 23492
Telephone: (847) 935-8337
Facsimile: (847) 938-2623



PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Carl M. Mendel, *et al.*

Serial No.: 10/828,607

Filed: April 24, 2004

For: TREATMENT OF NEUROPATHIC
PAIN

Examiner: L. Royds

Group Art Unit: 1614

Case No.: BBC128USC1

**CERTIFICATE OF MAILING (37 CFR
1.8 (a))**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450, on:

Date of Deposit: January 30, 2007

Kathleen Boettcher
Kathleen Boettcher

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The following information is submitted, pursuant to 37 CFR §§1.97-1.98 in accordance with Applicant's duty of disclosure under 37 CFR §1.56. This submission is not intended to constitute an admission that any patent, publication or other information cited herein is "prior art" as to the invention claimed. In accordance with 37 CFR §§1.97(g)-(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that other material information as defined by 37 CFR §1.56(a) exists.

Applicants submit herewith Form PTO 1449 listing the references cited in this Information Disclosure Statement. Applicants respectfully request that the Examiner (1) initial each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and (2) return a copy of the initialed Form PTO 1449 to Applicants. Copies of the cited references have been previously submitted in U.S. Patent Application Serial No. 09/528,798, filed October 12, 2004. The aforementioned earlier application is relied on for an earlier, patent application filing date under 35 U.S.C. 120.

This Information Disclosure Statement is submitted after the first Office Action on the merits, but before the issuance of a final action or a notice of allowance. Authorization to charge Deposit Account No. 01-0025 in the amount necessary to cover the cost of this Information Disclosure Statement under 37 C.F.R. 1.17(p) is provided in the Transmittal Letter, submitted herewith.

Respectfully submitted,
Carl M. Mendel, *et al.*



Andrew M. Parial
Registration No. 50,382
Attorney for Applicants

ABBOTT LABORATORIES
Customer Number: 23492
Telephone: (847) 935-8337
Facsimile: (847) 938-2623

DATE:

January 30, 2007SHEET 1 of 1

Form PTO - 1449 (Modified)



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
 (Modified) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT
 (Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.	SERIAL NO.
BBC128USC1	10/828,607
APPLICANT	
Carl M. Mendel, et al.	
FILING DATE	GROUP
April 21, 2004	1614

U.S. PATENT DOCUMENTS

EXAM. INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
	A1	4,522,828	06/11/1985	Jeffery, et al.			
	A2	4,939,175	07/03/1990	Ukai, et al.			
	A3	5,166,207	11/24/1992	Smith			
	A4	5,436,272	07/25/1995	Scheinbaum			
	A5	5,877,188	03/02/1999	McCullough, et al.			
	A6	6,004,927	12/21/1999	Benet, et al.			
	A7	6,323,242	11/27/2001	Mueller			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAM. INITIAL		DOCUMENT NUMBER	PUBLI-CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
B1		0 230 742	26.09.1990	EP				
B2		2 098 602	24.11.1982	GB				
B3		88/06444	07.09.1988	WO				
B4		90/06110	14.06.1990	WO				
B5		95/20949	10.08.1995	WO				
B6		98/41528	24.09.98	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

EXAM. INITIAL		
	C1	Adedoyin, A., et al., "Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail", <i>Br. J. Clin. Pharmacol.</i> , 46 :215-219 (1998)
	C2	Bloomgarden, Z.T., "The European Association for the Study of Diabetes Annual Meeting, 1998: The U.K. Prospective Diabetes Study and other topics in type 2 diabetes", <i>Diabetes Care</i> , 22 (6):989-995 (1999)
	C3	Hsu, A., et al., "Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents", <i>Clin. Pharmacol. Kinet.</i> , 35 (4):275-291 (1998)
	C4	Joos, A.A.B., et al., "Dose-Dependent Pharmacokinetic Interaction of Clozapine and Paroxetine in an Extensive Metabolizer", <i>Pharmacopsychiat.</i> , 30 :268-270 (1997)
	C5	Lurcott, G., "The Effects of the Genetic Absence and Inhibition of CYP2D6 on the Metabolism of Codeine and Its Derivatives, Hydrocodone and Oxycodone", <i>Anesth. Prog.</i> , 45 :154-156 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE:

January 30, 2007

SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

BBC128USC1

SERIAL NO.

10/828,607

APPLICANT

Carl M. Mendel, et al.

FILING DATE

April 21, 2004

GROUP

1614

U.S. PATENT DOCUMENTS

EXAM. INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
	A1	4,522,828	06/11/1985	Jeffery, et al.			
	A2	4,939,175	07/03/1990	Ukai, et al.			
	A3	5,166,207	11/24/1992	Smith			
	A4	5,436,272	07/25/1995	Scheinbaum			
	A5	5,877,188	03/02/1999	McCullough, et al.			
	A6	6,004,927	12/21/1999	Benet, et al.			
	A7	6,323,242	11/27/2001	Mueller			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAM. INITIAL		DOCUMENT NUMBER	PUBLI-CATION DATE	COUNTRY OR PATENT OFFICE	CLASS	TRANSLATION	
						SUB CLASS	YES NO
B1		0 230 742	26.09.1990	EP			
B2		2 098 602	24.11.1982	GB			
B3		88/06444	07.09.1988	WO			
B4		90/06110	14.06.1990	WO			
B5		95/20949	10.08.1995	WO			
B6		98/41528	24.09.98	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

EXAM. INITIAL		
	C1	Adedoyin, A., et al., "Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail", <i>Br. J. Clin. Pharmacol.</i> , 46:215-219 (1998)
	C2	Bloomgarden, Z.T., "The European Association for the Study of Diabetes Annual Meeting, 1998: The U.K. Prospective Diabetes Study and other topics in type 2 diabetes", <i>Diabetes Care</i> , 22(6):989-995 (1999)
	C3	Hsu, A., et al., "Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents", <i>Clin. Pharmacol. Kinet.</i> , 35(4):275-291 (1998)
	C4	Joos, A.A.B., et al., "Dose-Dependent Pharmacokinetic Interaction of Clozapine and Paroxetine in an Extensive Metabolizer", <i>Pharmacopsychiat.</i> , 30:268-270 (1997)
	C5	Lurcott, G., "The Effects of the Genetic Absence and Inhibition of CYP2D6 on the Metabolism of Codeine and Its Derivatives, Hydrocodone and Oxycodone", <i>Anesth. Prog.</i> , 45:154-156 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)